🔎 Trials Near Me

Domov › Prekomerna telesna teža › Texas › Houston

Klinične študije za Prekomerna telesna teža v Houston, TX

33 študij za Prekomerna telesna teža išče udeležence na lokacijah v Houston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Vključevanje udeležencevFaza 2
  • Juno Research /ID# 282413, Houston
  • PlanIt Research /ID# 282204, Houston
  • JCCT - Juno Bellaire /ID# 282263, Bellaire · 7 mi stran
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07752979

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Vključevanje udeležencevFaza 3
  • PlanIt Research, PLLC, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Vključevanje udeležencevFaza 3
  • DM Clinical, Houston
Starost 8–18 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07253285

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Vključevanje udeležencevFaza 3
  • Houston Research Institute, Houston
  • The Endocrine Center, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07668414

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Vključevanje udeležencevFaza 3
  • Biopharma Informatic, LLC, Houston
  • Care Access - Houston - Clinical Trials Center by Walmart & Care Access, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Vključevanje udeležencevFaza 3
  • PlanIt Research, LLC (Monitoring Room), Houston
  • PlanIt Research, LLC, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07595549

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Vključevanje udeležencevFaza 3
  • McGovern Medical School, Houston
  • Texas Childrens Hospital, Houston
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston
  • in še 1
Starost 6–17 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06672549

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Vključevanje udeležencevFaza 3
  • Juno Research, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Vključevanje udeležencevFaza 3
  • Juno Research, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Vključevanje udeležencevFaza 3
  • Research Site, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Vključevanje udeležencevFaza 3
  • Biopharma Informatic, LLC, Houston
  • Cardiovascular Specialists of Willowbrook, Houston
  • PlanIt Research, PLLC, Houston
  • in še 2
Starost 45–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Vključevanje udeležencevFaza 3
  • The University of Texas Health Science Center at Houston, Bellaire · 7 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Vključevanje udeležencevFaza 3
  • Care Access - Houston, Houston
  • JCCT - Juno Bellaire Site, Bellaire · 7 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Vključevanje udeležencevFaza 2
  • PlanIt Research, PLLC, Houston
Starost 18–75 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07589608

Semaglutide for Post-Smoking Cessation Weight Management

Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
  • The University of Texas Health Science Center at Houston, Houston
Starost 18–75 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06173778

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Vključevanje udeležencevFaza 3
  • AURORA-2 Clinical Site, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Vključevanje udeležencevFaza 3
  • HRI ? Medical Center, LLC, Houston
  • Juno Research, LLC, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Vključevanje udeležencevFaza 2
  • Juno Research, Houston
Starost 18–75 · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Vključevanje udeležencevFaza 3
  • Elevate Clinical, Houston
  • Houston Research Institute, Houston
  • Bellaire Clinical Research, LLC, Bellaire · 7 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
  • ACCOMPLISH-2 Research Site, Houston
  • ACCOMPLISH-2 Research Site, Houston
Starost 18–79 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07654374

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Vključevanje udeležencevFaza 3
  • Houston Pulm Med Res Network, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07571109

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Vključevanje udeležencevFaza 2
  • PlanIt Research, PLLC, Houston
Starost 18–75 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06143956

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Vključevanje udeležencevFaza 2
  • Biopharma Informatic, LLC, Houston
  • PlanIt Research, PLLC, Houston
  • Research Physicians Network, LLC, Houston
Starost 18–75 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07215559

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Vključevanje udeležencevFaza 4
  • Center for Clinical Studies, Houston
  • Bellaire Dermatology Associates, Bellaire · 7 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06857942

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Vključevanje udeležencevFaza 3
  • JCCT- Juno Northwest Houston, Houston
  • Biopharma Informatic, LLC, Houston
  • Johnson County Clinical Trials Juno Bellaire, Bellaire · 7 mi stran
Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Vključevanje udeležencevFaza 3
  • Kailera Clinical Site, Bellaire · 7 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Vključevanje udeležencevFaza 3
  • JCCT- Juno Northwest Houston, Houston
  • Johnson County Clinical Trials Juno Bellaire, Bellaire · 7 mi stran
Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07684144

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Vključevanje udeležencevFaza 3
  • Biopharma Informatic, LLC, Houston
  • Research Physicians Network, LLC, Houston
Starost 18–99 · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Vključevanje udeležencevFaza 3
  • Research Site, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Vključevanje udeležencevFaza 3
  • ACCOMPLISH-1 Research Site, Houston
  • ACCOMPLISH-1 Research Site, Houston
Starost 18–79 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT07654361

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Vključevanje udeležencevFaza 2
  • Baylor College of Medicine, Houston
Starost 18 in več · Vsi spoli · Posodobljeno 16. jan. 2026 · NCT06273072

Študije za Prekomerna telesna teža v drugih mestih

Druge študije v Houston

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.